Electric field cancer therapy solutions · SINCE 2017

Treating cancer with
electric fields.

From basic scientific research to precision delivery systems, FieldCure develops comprehensive solutions to plan, measure and reproduce electric field cancer therapy.

Explore products How the technology works
Precision electric field delivery research

Designing electric field delivery
for individual anatomy.

Research into alternating electric fields for cancer therapy focuses on disrupting cancer cell division. Precise delivery design is important because tissue properties and electrode placement affect field distribution.

FieldCure’s iMPACT technology combines patient-specific 3D models with electric field and thermal analysis to design electrode layouts and delivery conditions, and quantitatively compare results in regions of interest.

Explore iMPACT technology →Therapy principles and research evidence →
OncoField Lab showing a 3D anatomical model, electrode arrays and cross-sectional analysis results
OncoField Lab — research and education simulation software showing a 3D model, electrode placement and analysis results.

The iMPACT electric field delivery research workflow

  1. 01

    3D anatomical modelling

  2. 02

    Electrode & input design

  3. 03

    Electric field & thermal analysis

  4. 04

    Quantitative regional comparison

iMPACT Technology

We simulate and analyse electric field distribution and delivery conditions.

Explore iMPACT →
  • iIntensity modulated

    Electric field intensity is adjusted for each region of the electrode array.

  • MMultidirectional

    Multidirectional electric fields provide greater coverage of deep-seated tumours than fields applied in a single direction.

  • PPrecision

    Precise treatment plans are generated from patient-specific 3D models.

  • AAdaptive planning

    Plans are adjusted according to anatomical conditions and response as treatment progresses.

  • CConformal

    Electric fields are adjusted to suit the tumour target region (ROI), surrounding normal tissue and organs at risk (OAR).

  • TTemperature controlled

    Thermal effects are calculated, compared and analysed.

Ability A technology framework for designing and analysing electric field delivery conditions.

Community

Research findings published in international peer-reviewed journals since 2016
Press Releases →
MFDS Designates FieldCure iMET as Innovative Medical Device
Seoul, South Korea – September 25, 2025 – FieldCure announced that its electric field-based cancer therapy device, iMET, has been officially designated as an Innovative Medical Device (Technology Innovation Class) by the Ministry of Food and Drug Safety (MFDS) of Korea. The designation, granted under the Medical Device Industry Promotion and Innovative Medical Device Support Act, recognizes cutting-edge technologies expected to significantly improve patient outcomes and generate strong industrial impact. The Technology Innovation Class focuses on areas where the development and localization of core medical device technologies are urgently needed. iMET applies alternating electric fields at specific frequencies to selectively disrupt mitosis in rapidly dividing cancer cells while sparing normal cells that divide more slowly, thereby reducing side effects compared to conventional cancer therapies. 64-channel electrode control for precise field delivery AI-based treatment planning system for patient-specific optimization Multi-directional electric field focusing enabling 2–3× higher field concentration and shorter treatment times With this designation, iMET becomes eligible for priority review of clinical trial applications and regulatory approvals, as well as full-cycle technical support and programs that accelerate market entry—expected to further speed clinical development and commercialization. “This designation is highly meaningful as it represents a new paradigm in cancer treatment based on domestic core technologies rather than incremental improvements. We will focus our clinical studies on intractable cancers such as pancreatic cancer—where five-year survival is below 15%—to offer new treatment options for patients who do not respond to existing therapies.” — Myung-Geun Yoon, CEO of FieldCure Source: The Korea Economic Daily (September 25, 2025)
2025.11.03
Announcements →
FAQ →
What is electric field therapy, and who is it for?
Find answers to frequently asked questions about electric field-based cancer therapy, software licensing and research support.